-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie to buy Apogee Therapeutics for $135.11 per share in cash, valuing deal at $10.9 billion

PUBT·06/22/2026 11:07:28
Listen to the news
AbbVie to buy Apogee Therapeutics for $135.11 per share in cash, valuing deal at $10.9 billion
  • AbbVie agreed to buy Apogee Therapeutics for USD 135.11 per share in cash, valuing the equity at about USD 10.9 billion.
  • Closing is targeted for Q3 2026, subject to shareholder and regulatory approvals.
  • Deal adds Apogee’s late-stage IL-13 antibody zumilokibart for atopic dermatitis to AbbVie’s immunology pipeline.
  • AbbVie also gains APG273, a long-acting IL-13 and TSLP combination being developed for asthma.
  • AbbVie expects the transaction to be accretive to adjusted diluted EPS beginning in 2032.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.